Roche’s cobas BV/CV assay gains CE Mark, enabling accurate, rapid diagnosis of bacterial vaginosis and candida vaginitis.
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test ...
From respiratory infection to fatal neurological disease, EHV-1 demands rapid PCR diagnosis, and detection protocols impact ...
Sportschosun on MSN
In winter, respiratory infectious diseases are in vogue...What is the difference between PCR test an...
In winter, various respiratory infectious diseases such as influenza (flu), pneumonia, and COVID-19 are prevalent at the same ...
Roche announced the CE Mark for its cobas BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately identify specific bacteria and yeast responsible for BV and CV in vaginal samples from ...
Co-Diagnostics receives Australian patent covering Co-Dx PCR platform technologies for nucleic acid detection and analysis: Salt Lake City Wednesday, December 31, 2025, 11:00 Hrs ...
WHO noted that prequalified tests can now be prioritized in pooled procurement mechanisms, which help lower prices, stabilize ...
Earlier this year the Therapeutic Goods Administration (TGA) halted the sale of 21 sunscreen products in Australia following reports from consumer advocacy group CHOICE that Sun Protection Factor (SPF ...
Zacks Investment Research on MSN
CODX shares dip despite Australian patent grant for Co-Dx PCR platform
CoDiagnostics CODX recently announced that the Australian Patent Office has granted a patent covering its new Co-Dx PCR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback